Q2 EPS Estimates for OTCMKTS:BSEM Decreased by Analyst

BioStem Technologies, Inc. (OTCMKTS:BSEM) – Analysts at Zacks Small Cap cut their Q2 2025 earnings per share estimates for BioStem Technologies in a note issued to investors on Tuesday, May 13th. Zacks Small Cap analyst B. Sorensen now anticipates that the company will post earnings of $0.22 per share for the quarter, down from their previous estimate of $1.28. The consensus estimate for BioStem Technologies’ current full-year earnings is $1.41 per share. Zacks Small Cap also issued estimates for BioStem Technologies’ Q3 2025 earnings at $0.18 EPS, Q4 2025 earnings at $0.19 EPS and FY2026 earnings at $2.27 EPS.

BioStem Technologies Price Performance

OTCMKTS BSEM opened at $12.39 on Friday. The business has a fifty day moving average price of $11.29 and a two-hundred day moving average price of $13.92. BioStem Technologies has a fifty-two week low of $6.77 and a fifty-two week high of $28.26. The stock has a market capitalization of $206.96 million, a PE ratio of 18.22 and a beta of -0.10.

BioStem Technologies (OTCMKTS:BSEM) last released its earnings results on Monday, May 12th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $1.25 by ($1.08). The business had revenue of $72.53 million during the quarter, compared to analysts’ expectations of $101.20 million.

About BioStem Technologies

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.